Research Interest: Stem Cell Biology; Breast Cancer Dormancy; Neural Regulation of Hematopoiesis, the Immunology and Clinical Application of Adult Human Mesenchymal Stem Cells. 

Research Interest: Actually Works as Young Researcher in Projects Regarding Genomics, Proteomics and Inflammatory Aspects of Human Breast Cancer and Chronic Diseases. 

Research Interest: Genes Involved in Cell Cycle Regulation, Differentiation, Apoptosis and Senescence Such as the Retinoblastoma (RB) Family. He has Evaluated the Role of Retinoblastoma Genes in the Regulation of Cell Proliferation, Differentiation and Apoptosis in
Cancer and Normal Stem Cells. In Detail, his Group has Analyzed the Biology of Neural Stem Cells and Mesenchymal Stem Cells. These Studies Prompted the Attention Also on Chromatin
Remodeling Factors that Interact with RB Family Members and Play a Key Role in the Life of StemCells.

Research Interest: Stem Cells, Cancer, Immune Therapy, Regenerative Medicine.

Dr. Edgar Grinstein is a Principal Investigator at the Heinrich Heine University in Düsseldorf (Germany). He researches hematopoietic stem cells and progenitor cells, signal transduction, gene transcription regulation. He has more than 11 years of experience as Editor-In-Chief at SAGE Publications Inc. (USA) and Libertas Academica (New Zealand), and also serves as Deputy Editor-In-Chief for Baishideng Publishing Group (USA).

Raised in a family of researchers – both parents are PhD scientists - he received his PhD summa cum laude in Molecular Biology from the Humboldt University and the Max-Delbrück Center for Molecular Medicine in Berlin. He has published a number of papers in high-ranking journals and received a highly regarded Research Award from Dr.-Günther- and Imme-Wille-Foundation. Dr. Grinstein qualified as Professor in Molecular Medicine at the University of Düsseldorf in 2008 and is a Visiting Professor at the University of Latvia (Latvia, European Union) since 2010.  

Dr. Grinstein`s research in the field of hematopoietic stem and progenitor cells, funded by research grants from German Research Foundation (DFG) and José Carreras Leukämie-Stiftung (José Carreras Foundation), has focused on markers, signal transduction and transcriptional control. Among other important findings made, his research group provided new insights into the role of the prominent surface marker AC133/CD133 (Leukemia 2015; 29: 2208-2220), that is expressed on stem/progenitor cells in normal hematopoiesis as well as on tumor-initiating cells in certain hematological malignancies. The study analyzed the control of AC133/CD133 expression in hematopoietic stem/progenitor cells, and revealed the impact thereof on molecular network relevant to these cells.

Research Interest: hematopoietic stem cells and progenitor cells, cancer stem cells, stem cell markers, signal transduction, cell cycle control, regulation of apoptosis, gene transcription regulation

Grants: Principal Investigator of stem cell-related projects funded by German Research Foundation (DFG) and by José Carreras Leukämie-Stiftung (José Carreras Foundation)

URL: https://www.wjgnet.com/2218-6204/MemberDetail/42530

publications:

Grinstein, E., and H.-D. Royer. 1995. Multiple octamer-binding proteins are targets for the cell cycle regulated nuclear inhibitor I-92. DNA Cell Biol. 14: 493-500.

Grinstein, E., I. Weinert, B. Droese, M. Pagano, and H.-D. Royer. 1996. Cell cycle regulation of nuclear factor p92 DNA-binding activity by novel phase-specific inhibitors. J. Biol. Chem. 271: 9215-9222.

Bargou, R.C., C. Wagener, K. Bommert, W. Arnold, P.T. Daniel, M.Y. Mapara, E. Grinstein, H.-D. Royer, and B. Dörken. 1996. Blocking of transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J. Exp. Med. 183: 1205-1213.

Bargou, R.C., F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, W. Arnold, H.-D. Royer, E. Grinstein, A. Greiner, C. Scheidereit, and B. Dörken. 1997. Constitutive nuclear factor kappaB-RelA activation is required for proliferation and survival of Hodkin’s desease tumor cells. J. Clin. Invest. 12: 2961-2969.

Janke, J., K. Schlüter, B. Jandrig, M. Theile, K. Kölble, W. Arnold, E. Grinstein, A.  Schwartz, L.E. Schwarz, P.M. Schlag, B.M. Jockusch, and S. Scherneck. 2000. Suppression of tumoriginecity in breast cancer cells by the microfilament protein profilin1. J. Exp. Med. 191: 1675-1685.

Grinstein, E.,* F. Jundt, I. Weinert, P. Wernet, and H.-D. Royer. 2002. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 21: 1485-1492.

Grinstein, E., P. Wernet, P.J. Snijders, F. Rösl, I. Weinert, W. Jia, R. Kraft, Ch. Schewe, M. Schwabe, S. Hauptmann, M. Dietel, Ch. Meijer, and H.-D. Royer. 2002. Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer. J. Exp. Med. 196: 1067-1078.

Grinstein, E.,* Y. Shan, L. Karawajew, P.J. Snijders, C.J. Meijer, H.-D. Royer, and P. Wernet. 2006. Cell cycle controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation.  J. Biol. Chem. 281: 22223-22235.

Grinstein, E.,* Y. Du, S. Santourlidis, J. Christ, M. Uhrberg, and P. Wernet. 2007. Nucleolin regulates gene expression in CD34 positive hematopoietic cells. J. Biol. Chem. 282: 12439-12449.

Grinstein, E.,* and P. Wernet. 2007. Cellular signaling in normal and cancerous stem cells. Cell. Signal. 19: 2428-2433.
This was the most read article of the Journal Cell. Signal. from July 2007 till March 2008. Source: SCIENCEDIRECT TOP 25 HOTTEST ARTICLES

Wethkamp, N., H. Hanenberg, C. Suschek, W. Wetzel, S. Heikaus, E. Grinstein, U. Ramp, R. Engers, H. Gabbert, and C. Mahotka. 2011. DAXX-beta and DAXX-gamma: two novel splice variants of the transcriptional co-repressor DAXX. J. Biol. Chem. 19576-19588.

Grinstein, E.,* C. Mahotka, and A. Borkhardt. 2011. Rb and nucleolin antagonize in controlling human CD34 gene expression. Cell. Signal. 23: 1358-1365.

Bhatia, S., S. Reister, C. Mahotka, R. Meisel, A. Borkhardt, and E. Grinstein.* 2015. Control of AC133 / CD133 and impact on human hematopoietic progenitor cells through nucleolin. Leukemia. 29: 2208-2220.

Mahotka, C., S. Bhatia, J. Kollet, and E. Grinstein.* 2018. Nucleolin promotes execution of the hematopoietic stem cell gene expression program. Leukemia. 32: 1865–1868.

Reister, S., C. Mahotka, N. van den Höfel, and  E. Grinstein.* 2019. Nucleolin promotes Wnt signaling in human hematopoietic stem/progenitor cells. Leukemia. 33: 1052-1054.

Research Interest: Cardiac Therapy, Cardiovascular Disease, Autologous, Tissue-Engineering, Multipotent Stem Cells, Cardiovascular Structures, Regenerative Medicine.

Research Interest: Hematopoietic Stem Cell Transplanting, Cell Therapy and Everything in the Field of Publication and Education.

Research Interest: Cancer Stem Cell, Anticancer Agent, Metastasis, Cell Survival, Cell Migration, Apoptosis, Molecular and Cell Signaling, Transcription Factors, Xenograft Model, Stem Cell Based Therapy.

Research Interest: Cancer Metabolism, Metabolomics, NMR and MRI Methods, Systems Biology.

Research Interest: As Is Clear From The Biography, Shigetaka Asano Accomplisheddistinguished Performance In Research Based On Medical Needs By Full Of Enthusiasm With State-Of-The-Art New Technology, Such As 1. Verification Of Existence Of Rabbit Neutrophil Cell Membrane Knack+-Atpase, 2. Discovery Of Laterarity Of Mouse Intestinal Mucous Membrane Proteins, 3. Finding Of Human Tumor Cell Mediated By Granulocyte Colony-Stimulating Factor (G-CSF; Bioactive Substance To Stimulate Differentiation, Proliferation And Functional Activity Of Neutrophil), 4. Analysis Of Human G-CSF Activity, 5. Succeeding In Incubation Of Human Tumor Infiltrating T Lymphocyte Colony, 6. Discovery Of Allogenicimmunosuppression Of Placenta Decidual Cells, 7. Differentiation Induction Of Mesenchymalstem Cell, 8. Cloning Of G-Csfcdna And Development Of Recombinant Human Native G-CSF (Lenograstim) As The 1st Generation Biomedicine, 9. Constitution Of International Clinical Guideline For Transplantation Of Bone-Marrow And Cord Blood, And Construction Of Public Bank Of Bone-Marrow And Cord Blood, 10. Non-Clinical Study Of Human Granulocyte Colony-Stimulating Factor (GM-CSF; Bioactive Substance To Stimulate Differentiation, Proliferation And Functional Activity Of Macrophage Besides Neutrophil)Immunogene Therapy And Execution Of The Phase Iia Clinical Study, 11. Non-Clinical Study Of Utilizing Maxizyme For Immunogene Therapy Of Myeloid Leukemia Cell, 12. Acquisition And Molecular Analysis Of Leukemia Stem Cell Like Property By Stochastic Adhesion Of In Vitro Human Myelogenous Leukemic Cell Line Cell And Stromal Cell, 13. Pathological Analysis Of Mesenchymalstem Cell(Parental Cell Of Range Of Cell Consist Ofstroma) Differentiation And Proliferation In Translin(Substance Found As Molecule To Bind Fusion Gene Of Lymphatic Leukemia) Knockout Mouse. 

Research Interest: Clinical Nephrology, Metabolic Syndrome, Hypertension, Inflammation

Research Interest: Centered on Translational Oncology with Main Emphasis on Identification of Novel Targets in Cancer Stem Cells, Validation of Targeted Cancer Therapeutics, Nanomedicine and Drug Development Program.

Dr. Monther AlAlwan is a scientist at the Stem Cell and Tissue Re-engineering Program (SCTRP), King Faisal Specialist Hospital and Research Centre, as well as an Associate professor at Alfaisal University, Riyadh Saudi Arabia. He holds M.Sc. and Ph.D. in Immunology from Dalhousie University (Halifax, Canada). Dr. AlAlwan conducted a 3-years postdoctoral fellowship studying signaling in immune cells at the University of Manitoba, Canada. During his graduate studies and postdoctoral fellowship, Dr. AlAlwan made substantial contribution in the immunology field, particularly his groundbreaking discovery that highlighted the significance of the dendritic cells in the immunological synapse. After joining the SCTRP in 2007, he shifted gear to study cancer, where he identified novel mechanisms that regulate cancer metastasis and chemoresistance. Currently, he is actively involved in dissecting the molecular pathways that regulate the function of cancer stem cells and how this related to chemoresistance and metastasis. Dr. AlAlwan is an author in 20 peer-reviewed publications, has delivered several invited lectures and is a regular reviewer for various international journals.   

Research Interest: Effects of Chinese Herbal Medicine on Osteogenesis and Adipogenesis of Mesenchymal Stem Cells, Inhibitory Effects of Chinese Herbal Medicine on RANKL-Induced Osteoclastgenesis of RAW264.7 Cells, Effect of Chinese Herbal Medicine on Different Osteoporotic Rat Models, Establishment of the Screening Platform for Neuro-Regenerative Chinese Herbal Medicine by Using Rat Mesenchymal Stem Cells, Topical Application of Chinese Medicine in Musculoskeletal Injuries, Wound Healing, Cancer Stem Cells, Neuroprotection.

Research Interest: Nanotechnology, Bioanalytical chemistry, infectious disease diagnosis, cellular analysis